Kornimate/medical-research-clean huggingface dataset:
a multiomics study based on the dynamic evolution of endometrial carcinogenesis

Conditions: the Dynamic Evolution of Endometrial Carcinogenesis; Multiomics Analysis

Summary: the goal of this observational study is to draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium, 100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial cancer; and then to explore the underlying molecular mechanism, and establish the database system for the dynamic evolution of endometrial carcinogenesis.


Eligibility criteria:
inclusion criteria: * pathological diagnosis: normal endometrium, atypical hyperplasia endometrium, or endometrial cancer; * obtain pathological results after undergoing hysteroscopic surgery or hysterectomy; * the patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements; * sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests. exclusion criteria: * patients with malignant tumors in other parts of the body; * suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders; * poor compliance and inability to cooperate and describe treatment responders.

Keywords: dynamic evolution genomics transcriptome proteomics metabolomics
vinorelbine metronomic plus bevacizumab as salvage therapy for breast cancer

Conditions: Breast Cancer

Summary: to evaluate the efficacy of metronomic oral vinorelbine taken three times a week without break plus bevacizumab as salvage treatment in patients with metastatic breast cancer.

continuous administration of oral vinorelbine, given three times a week (metronomic) is feasible and exceptionally well tolerated at doses up to 50 mg. early results show activity against refractory tumors and provide evidence towards clinical proof of efficacy for metronomic chemotherapy. recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone.

Eligibility criteria:
inclusion criteria: * histologically- or cytologically- confirmed metastatic breast adenocarcinoma * at least one previous chemotherapy regimen for metastatic breast cancer * age 18-75 years * measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions) * performance status (who) 0-2 * adequate liver function(serum bilirubin \<1.5 times the upper normal limit, ast and alt \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases), adequate renal function (serum creatinine \<1.5 times the upper normal limit) and bone marrow (neutrophils ≥ 1.5x 109 /l, and platelets ≥ 100x 109 /l) function * no radiation of measurable disease (except brain metastases) * no progressive brain metastases according to clinical or radiological criteria * no brain metastases without prior radiation therapy * written informed consent exclusion criteria: * patient unable to take oral medication * active infection * history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * history of stroke * anticoagulation therapy (except of low dose aspirin \<325mg) * other invasive malignancy except nonmelanoma skin cancer * psychiatric illness or social situation that would preclude study compliance * pregnant or lactating women

Keywords: breast cancer chemotherapy anti-angiogenesis therapy
double guidewire technique versus transpancreatic precut in patients with repetitive unintentional cannulation of the pancreatic duct.

Conditions: Endoscopic Retrograde Cholangiopancreatography; Common Bile Duct Diseases; Transpancreatic Precut; Precut; Double Guidewire

Summary: difficult cannulation of the common bile duct is encountered in about 10%of ercp procedures. this frequently happens in the form of repeated unintentional cannulation of the pancreatic duct. two valid options are available to facilitate cannulation at this point: double guidewire technique or performing a transpancreatic precut. this is a randomized trial comparing the efficacy and safety of double guidwire technique versus transpancreatic precut after three unintentional passages of the guidewire into the pancreatic duct.


Eligibility criteria:
inclusion criteria: * unintentional cannulation of the pancreatic duct 3 times * consenting to join the study exclusion criteria: * previous ercp with or without previous sphincterotomy * known coagulopathy * - pregnancy * - known acute pancreatitis at the time of procedure
safety and efficacy of natalizumab in the treatment of multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (ms). it is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). these white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. these lesions are thought to be the cause of relapses and disability in ms.


Eligibility criteria:
inclusion criteria: * diagnosis of ms, as defined by mcdonald et al., criteria # 1-4 (mcdonald et al., 2001) * between the ages of 18 and 50, inclusive. * baseline edss score between 0.0 and 5.0, inclusive. * have experienced at least one relapse within the 12 months prior to randomization. * cranial mri scan demonstrating lesion(s) consistent with ms. * have given written informed consent to participate in the study. exclusion criteria: * primary progressive, secondary progressive, or progressive relapsing ms. * ms relapse has occurred,in the opinion of the investigator, within 50 days prior to randomization and/or the subject has not stabilized from a previous relapse. * a clinically significant infectious illness within 30 days prior to randomization. * history of, or abnormal laboratory results indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal and/or other major disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent for 116 weeks. * history of severe allergic or anaphylactic reactions or known drug hypersensitivity. * unable to perform the timed 25-foot walk, 9hpt, and pasat 3. * abnormal blood tests performed at the screening visit.

Keywords: relapsing remitting multiple sclerosis
long-term safety extension trial of asenapine in schizophrenia participants who completed protocol p05688 (p05689)

Conditions: Schizophrenia

Summary: participants who have completed the 6-week trial p05688 can be screened for eligibility for this 26-week extension study in which they will continue treatment. the purpose of this trial is to evaluate the long-term safety of 2.5 and 5 mg asenapine administered sublingually twice daily (bid) in schizophrenia participants. olanzapine administered 15 mg orally once daily (qd) is used as an active control.


Eligibility criteria:
inclusion criteria: * completed the short-term trial p05688, and judged by the investigator likely to benefit from continued treatment exclusion criteria: * occurrence(s) of an adverse event or other clinically significant finding(s) in the short-term trial p05688 that would prohibit the participant's continuation into the long-term extension * clinical global impression-severity of illness (cgi-s) score of ≥6 (severely psychotic) at baseline * newly diagnosed or discovered psychiatric condition that would have excluded the participant from participation in the short-term trial p05688
effectiveness of video-game based swallowing function training in patients with dysphagia

Conditions: Deglutition Disorders; Rehabilitation; Video Game

Summary: the goal of this clinical trial is to investigate the effect of video-game on swallowing function in patients with dysphagia through a randomized controlled trial and whether it has additional benefits in improving swallowing function and training compliance compared with conventional training methods. the main questions it aims to answer are: * how effective is video-game based rehabilitation for dysphagia? * whether video-game based has additional benefits in improving swallowing function and training compliance compared with conventional training methods participants will be divided into two groups, with one group completing video game rehabilitation and one group completing conventional rehabilitation.


Eligibility criteria:
inclusion criteria: 1. first-episode stroke, as confirmed by brain ct or mri; 2. diagnosis of dysphagia after stroke according to the toronto bedside swallowing screening test (tor-bsst); 3. age between 18 and 80 years; 4. no significant cognitive impairment, able to execute instructions correctly, and with mini-mental state examination (mmse) score ≥ 24; 5. clear consciousness as assessed by the national institute of health stroke scale (nihss). exclusion criteria: 1. dysphagia caused by structural lesions (eg, radiotherapy, previous extensive surgery of the head and neck region such as laryngectomy and cordectomy); 2. combined with serious heart, lung, liver, kidney diseases, and hematological disorders; 3. limb deficiency or paralysis, blindness in both eyes, severe visual impairments; 4. motion sickness or vestibular dysfunction; 5. history of epilepsy, malignancy or other neurological diseases; 6. pregnancy or breastfeeding.
drug-drug interaction study of glucokinase activator hms5552 and metformin in t2dm

Conditions: Type 2 Diabetes Mellitus

Summary: this is a phase 1, open-label, sequential, multiple-dose, drug-drug interaction study of gk activator hms5552 and metformin in patients with type 2 diabetes mellitus (t2dm).

this is a phase 1, open-label, sequential, multiple-dose, drug-drug interaction study of gk activator hms5552 and metformin in patients with type 2 diabetes mellitus (t2dm). the study is to assess the potential pharmacokinetic interaction between hms5552 and metformin in subjects with t2dm. the study is also to evaluate the safety and tolerability of hms5552 with simultaneous administration of metformin in subjects with t2dm.

Eligibility criteria:
inclusion criteria: * male and/or female subjects between the ages of 18 and 70 years * body mass index (bmi) of approximately 22 to 38kg/m2 * hba1c ≥7% and ≤12% * are capable of giving informed consent and complying with study procedures exclusion criteria: * fasting blood glucose ≤110 or ≥270mg/dl * type 1 diabetes mellitus, or latent autoimmune diabetes in adults * history or symptoms of clinically significant cardiovascular disease, particularly coronary artery disease, arrhythmias, atrial tachycardia, or congestive heart disease within one year of screening * history of liver disease and clinically significant renal disease * known hypersensitivity to metformin hydrochloride; * positive pregnancy test result;
study evaluating hki-272 administered to healthy subjects

Conditions: Healthy

Summary: safety and tolerability of hki-272 in healthy subjects; the influence of food intake on the same.


Eligibility criteria:
inclusion criteria: * healthy

Keywords: breast cancer health pharmacokinetics healthy subjects
the impact of oral health literacy on dental anxiety and utilization of oral health services

Conditions: Oral Health

Summary: oral health literacy is an integral part that should be taken into measures when evaluating the oral health status of any population. it has been stated that adults with low oral health literacy are more prone to miss their dental appointments and that low levels of oral health literacy, and being anxious and fearful of the dentist is a common barrier to the utilization of dental services. unfortunately no previous studies assessed the oral health literacy level, dental anxiety and utilization of dental services among the egyptian population. so the aim of the current study is to detect the impact of oral health literacy on level of dental anxiety and utilization of dental services among misr international university (miu) dental patients.

the current study is a cross sectional study that includes an interview lead questionnaire that will be carried out by second year dental students of the academic years (2018-2019, 2019- 2020). the questionnaire consists of four sections; a demographic section, a modified arabic rapid estimate of adult literacy (arelad-30) tool, arabic modified dental anxiety scale (amdas), and utilization of oral health services questionnaire. before conducting the study, orientation sessions and thorough training of the students will be performed to ensure that the students can conduct the interview consistently and efficiently. students will be asked to design educational materials (brochures, leaflets and posters) that aim at improving patients' knowledge and awareness regarding oral health and the utilization of oral health services. the aim of this study is to detect the impact of oral health literacy on the level of dental anxiety and utilization of dental services among dental patients.

Eligibility criteria:
inclusion criteria: * both genders. * age: 18 - 60 years old. * dentate or partially edentulous patients with or without fixed or removable appliances. * healthy adults as well as adults with any chronic condition and/or under regular use of medication. exclusion criteria: * subjects with mental or psychological problems. * subjects who cannot read or write.

Keywords: oral health literacy dental anxiety utilization of oral health services dental patients
breeze3:study of gabapentin extended release in the treatment of vasomotor symptoms(hot flashes)in postmenopausal women

Conditions: Hot Flashes

Summary: depomed's gabapentin extended release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes/hot flushes in postmenopausal women

the primary study objective is to assess the efficacy of g-er dosed at 1800mg daily (600mg am, 1200mg pm), compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women at weeks 4 \& 12 of the efficacy treatment period, compared with baseline.

Eligibility criteria:
inclusion criteria: * generally healthy, postmenopausal women who seek treatment for hot flashes * patients using hormone replacement therapy(hrt) must be willing to discontinue treatment * patients must be experiencing moderate to severe hot flashes * patients must be able to sign the informed consent * patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary other inclusions apply. exclusion criteria: * patients with hypersensitivity to gabapentin * patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (ibs) or unexplained weight loss * patients treated with estrogen pellets or injectable progestin drug therapy within 6 months. * patients currently treated with gabapentin or pregabalin for any indication, including vasomotor symptoms other exclusions apply.

Keywords: hot flushes vasomotor symptoms menopausal hot flashes
bowel dysfunction and holep outcomes

Conditions: Urologic Injuries

Summary: the objective of this prospective study is to examine the correlation and effects of bowel dysfunction on outcomes for patients undergoing holmium laser enucleation of prostate (holep) for lower urinary tract symptoms secondary to benign prostatic hyperplasia (bph).the investigator hypothesizes that patients who have more bowel dysfunction based on higher severity scores on patient-reported validated questionnaires will experience more symptoms in the immediate post-operative period and may have slower recovery of urinary control. assessment of pre, peri, and post-procedural bowel dysfunction via the constipation severity score (css) and vaizey incontinence questionnaire will aid the analysis.


Eligibility criteria:
inclusion criteria: * males18-89 undergoing holep * able to read, understand, and complete patient questionnaires * willing to sign the informed consent form exclusion criteria: * patients with bowel diversion (colostomy, ileostomy) * patients with known neurogenic bowel * patients having concurrent ureteroscopy+/-laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at time of holep * anticipated need for perineal urethrostomy at time of holep * prior pelvic radiation or patients with history of bladder cancer with or without bacillus calmette-guerin (bcg) therapy * patients who lack decisional capacity
cognitive changes in mild cognitive impairment

Conditions: Healthy Controls Without Orthostatic Hypotension

Summary: background: in recent years, the changes of cognitive function in mild cognitive impairment have attracted attention. methods/design: we will follow up at 3. the primary outcome will be the measurement of cognitive function using neuropsychological assessment scales such as moca, mmse, etc... minor variables will be included plasma biomarkers (aβ, tau, gfap, etc.), multimodal brain electrophysiology (p300, vp300, heart rate variability, etc.), and neuroimaging indicators (noddi).


Eligibility criteria:
inclusion criteria: * clinically diagnosed mild cognitive impairment exclusion criteria: * patients with orthostatic hypotension * patients with other neurological disorders. * pregnant or lactating women.

Keywords: cognition
deep transcranial magnetic stimulation (tms)- treatment for post traumatic stress disorder

Conditions: Post Traumatic Stress Disorder

Summary: evaluation of the novel deep tms h-coil designs as a treatment measure in post traumatic stress disorder (ptsd). comparing real to sham treatment.


Eligibility criteria:
inclusion criteria: * ptsd diagnosis per dsm iv exclusion criteria: * schizophrenia * bipolar i * severe axis ii diagnosis * risk factors to convulsions * drug / alcohol abuse

Keywords: ptsd
oral manifestations of aplastic anemia

Conditions: Aplastic Anemia

Summary: the purposes of this study are threefold: 1) to evaluate the prevalence and risks of oral complications in patients with aplastic anemia; 2) to evaluate if oral problems in these patients can predict their response to treatment; and 3) to review complications of dental treatment in these patients in order to establish treatment guidelines. this study will be performed through a review of medical charts of 79 patients with aplastic anemia and 67 patients with schizophrenia who were treated at the national institutes of health dental clinic between 1993 and 1999. the schizophrenia patients will serve as a control population. demographic, clinical and radiographic information will be collected for all patients. additional data collected only for aplastic anemia patients will include medical therapy, disease duration, blood cell counts, oral problems that developed during treatment and treatment response.

the prevalence, risk factors and significance of oral manifestations in aplastic anemia have not been well characterized. thus, in the present study, through a retrospective chart review, we document the prevalence of oral complications in aa patients and the risks for oral manifestations in a case-control study. schizophrenic patients represent controls. information includes the following; demographic, clinical and radiographic information for cases and controls. additional data collection for only aa patients includes prior medical therapy, cbc and differential, disease duration, new oral manifestations during aa treatment and medical treatment response. we determine if systemic clinical features of aa predict oral manifestations, and if oral manifestations predict treatment outcomes for aa patients. finally complications following dental treatment are compiled and reviewed to establish initial treatment guidelines for these patients.

Eligibility criteria:
inclusion criteria: cases: all aplastic anemia patients evaluated at the nih dental clinic for consultation between 1993-1999. controls: all schizophrenic patients evaluated at the nih dental clinic for consultation between 1993-1999. exclusion criteria: patients without the diagnosis of aplastic anemia for cases or schizophrenia for the controls.

Keywords: immunosuppression treatment recommendations pancytopenia schizophrenia inpatient population
the role of induction chemotherapy for high-risk locally advanced nasopharyngeal carcinoma in the era of imrt

Conditions: Nasopharyngeal Neoplasms

Summary: the purpose of this study is to determine whether intensity-modulated radiation therapy (imrt) combined inductive and concurrent chemotherapy with more intensive regimen (cisplatin and paclitaxel) is feasible and effective than current standard treatment for high-risk locally advanced npc patients.

meta-analysis showed chemotherapy when combined with conventional radiotherapy in locally advanced naso-pharyngeal carcinoma can improve 5-year overall survival with 6%, and beyond all concurrent chemotherapy with cisplatin benefits most. however, from lin's (lin jc, 2004) study, locally advanced npc with high risk factors can not benefit from conventional concurrent chemoradiation. failure pattern analysis revealed that local and distant failure accounted for 50% respectively. large-scale data has demonstrated that with imrt, local control can achieve 90%. previous studies showed inductive chemotherapy can decrease distant metastasis. we need more effective and stronger chemotherapy, and we still need to testify concurrent chemotherapy combined with inductive chemotherapy. a prospective trial would thus provide valuable information to help physicians and patients more precisely identify the feasibility and effectiveness of inductive + concurrent chemotherapy combined with imrt for high-risk locally advanced npc.

Eligibility criteria:
inclusion criteria: * biopsy-proved npc * n3 or t4n2 or multiple lymphnodes involved with at least one mass 4 cm or more in maximal diameter according to 7th uicc staging * provide written informed consent * kps\>70 * no dostant metastasis * life expectancy≥6 months * adequate renal function, defined as follows: serum creatinine \< 2 x institutional upper limitof normal(uln) within 2 weeks prior to registration or; creatinine clearance rate (ccr) ≥ 50 ml/min within 2 weeks prior to registration determined by 24- hour collection or estimated by cockcroft-gault formula: ccr male = \[(140 - age) x (wt in kg)\] \[(serum cr mg/dl) x (72)\] ccr female = 0.85 x (ccrmale) * the following assessments are required within 2 weeks prior to the start of registration: na, k, cl, glucose, ca, mg, and albumin. exclusion criteria: * prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated \< 3 years ago * prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * severe, active co-morbidity

Keywords: adjuvants inductive concurrent chemoradiotherapy high-risk locally advanced npc